The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer
Abstract
Purpose: The optimal radiation dose fractionation schedule for localized prostate cancer is unclear. This study was designed to compare two dose fractionation schemes (a shorter 4-week radiation schedule v a longer 6.5-week schedule). Patients and Methods: Patients with early-stage (T1 or T2) prostate cancer were randomly assigned to 66 Gy in 33 fractions over 45 days (long arm) or 52.5 Gy in 20 fractions over 28 days (short arm). The study was designed as a noninferiority investigation with a predefined tolerance of −7.5%. The primary outcome was a composite of biochemical or clinical failure (BCF). Secondary outcomes included presence of tumor on prostate biopsy at 2 years, survival, and toxicity. Results: From March 1995 to December 1998, 936 men were randomly assigned to treatment; 470 were assigned to the long arm, and 466 were assigned to the short arm. The median follow-up time was 5.7 years. At 5 years, the BCF probability was 52.95% in the long arm and 59.95% in the short arm (difference = −7.0%; 90% CI, −12.6% to −1.4%), favoring the long arm. No difference in 2-year postradiotherapy biopsy or in overall survival was detected between the arms. Acute toxicity was found to be slightly higher in the short arm (11.4%) compared with the long arm (7%; difference = −4.4%; 95% CI, −8.1% to −0.6%); however, late toxicity was similarly low in both arms (3.2%). Conclusion: Given the results, we cannot exclude the possibility that the chosen hypofractionated radiation regimen may be inferior to the standard regimen. Further evaluation involving higher dose hypofractionated radiation regimens in contemporary radiation settings is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D. A., & Rosen, I. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02829-8 · Cited by 1,333
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Zelefsky, M. J., Fuks, Z., Hunt, M., Yamada, Y., Marion, C., Ling, C. C., Amols, H., Venkatraman, E. S., & Leibel, S. A. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02857-2 · Cited by 775
Brenner, D. J., Martinez, A. A., Edmundson, G. K., Mitchell, C., Thames, H. D., & Armour, E. P. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02664-5 · Cited by 650
Is α/β for prostate tumors really low?
Fowler, J., Chappell, R., & Ritter, M. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01607-8 · Cited by 628
Zelefsky, M. J., Cowen, D., Fuks, Z., Shike, M., Burman, C., Jackson, A., Venkatramen, E. S., & Leibel, S. A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990601)85:11<2460::aid-cncr23>3.0.co;2-n · Cited by 336
Postradiotherapy prostate biopsies: what do they really mean? results for 498 patients
Crook, J., Malone, S., Perry, G., Bahadur, Y., Robertson, S., & Abdolell, M. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00637-4 · Cited by 257
Nahum, A. E., Movsas, B., Horwitz, E. M., Stobbe, C. C., & Chapman, J. D. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00534-0 · Cited by 218
Kupelian, P. A., Reddy, C. A., Carlson, T. P., ALTSMAN, K. A., & Willoughby, T. R. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02836-5 · Cited by 132
Kupelian, P. A., Reddy, C. A., Klein, E. A., & Willoughby, T. R. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01730-8 · Cited by 118
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Cited by
Zietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T., Mamedov, A., & Loblaw, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1192 · Cited by 1,221
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.003 · Cited by 1,113
Catton, C. N., Lukka, H., Gu, C.-S., Martin, J. M., Supiot, S., Chung, P. W. M., Bauman, G. S., Bahary, J.-P., Ahmed, S., Cheung, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7397 · Cited by 713
Self-citationWilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-6-200803180-00209 · Cited by 597
Metadata
- Authors
- Lukka, H., Hayter, C., Julian, J. A., Warde, P., Morris, W. J., Gospodarowicz, M., Levine, M., Sathya, J., Choo, R., Prichard, H., Brundage, M., & Kwan, W.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-01
- Volume
- 23
- Issue
- 25
- Pages
- 6132-6138
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115675646
- Cited by
- 349
- References
- 12
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.